biostudies-literatureUnknown81(5)Jouvenot G<h4>Importance</h4>A recent randomized clinical trial concluded that discontinuing medium-efficacy therapy might be a reasonable option for older patients with nonactive multiple sclerosis (MS), but there is a lack of data on discontinuing high-efficacy therapy (HET). In younger patients, the discontinuation of natalizumab and fingolimod is associated with a risk of rebound of disease activity.<h4>Objective</h4>To determine whether discontinuing HET in patients 50 years and older with nonactive MS is associated with an increased risk of relapse compared with continuing HET.<h4>Design, setting, and participants</h4>This observational cohort study used data from 38 referral centers from the French MS registry (Observatoire Français de la Sclérose en Plaques [OFSEP] database). Among 84704 patJAMA neurology490-498https://www.ebi.ac.uk/biostudies/studies/S-EPMC10964164biostudies-literatureHigh-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.PMC10964164Collongues NLe Page ELabauge PKerbrat AHeinzlef OGiannesini CDebouverie MPachot ARollot FMoreau TKremer LCasez OBakchine SVukusic SHankiewicz KCotton FMaurousset AZephir HCiron JThouvenot ELefort MPapeix CCabre PMoulin SMaillart EWiertlewsky SBerger EGuillememin FJouvenot GOFSEP InvestigatorsDouek PAudoin BPelletier JCamdessanche JPClavelou PMichel LMaubeuge NDefer GNeau JPDoghri IPottier CEdan GMagy LStankoff BMontcuquet Ade Seze JLabeyrie CBigaut KLubetzki CRigaud-Bully CCasey RMathey GBourre BNifle CCohen MLebrun-Frenay CWahab AFromont AGout OBen-Nasr HAl-Khedr AMarignier RCourbon GLaplaud DARuet AOlaiz JfalseHigh-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.<h4>Importance</h4>A recent randomized clinical trial concluded that discontinuing medium-efficacy therapy might be a reasonable option for older patients with nonactive multiple sclerosis (MS), but there is a lack of data on discontinuing high-efficacy therapy (HET). In younger patients, the discontinuation of natalizumab and fingolimod is associated with a risk of rebound of disease activity.<h4>Objective</h4>To determine whether discontinuing HET in patients 50 years and older with nonactive MS is associated with an increased risk of relapse compared with continuing HET.<h4>Design, setting, and participants</h4>This observational cohort study used data from 38 referral centers from the French MS registry (Observatoire Français de la Sclérose en Plaques [OFSEP] database). Among 84704 pat2024-01-01T00:00:00Z2024 May2025-06-25T03:04:32.279Z2025-06-25T03:04:32.279ZS-EPMC109641643852646210.1001/jamaneurol.2024.0395